Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection

Hepatitis delta: Epidemiology to recent advances in therapeutic agents

“…Furthermore, the novel therapeutic agents found to be effective in chronic HBV infection in various Phase II studies, such as small interfering RNA affecting envelopment (Figure 1), antisense oligonucleotide RNA, and anti-HBs antibodies, may prove to be beneficial in treating chronic HDV in future trials. [191][192][193][194][195][196] RNA interference pathway may inhibit viral genes and possibly cccDNA in chronic HBV infection. [191] TRANSPLANT Liver transplant remains a crucial therapeutic measure due to the lack of successful therapies as patients have rapid progression to decompensated cirrhosis and HCC.…”

“…Targeting the interaction of S-HDAg with these host factors might open further therapeutic options in the future (Figure 1). Furthermore, the novel therapeutic agents found to be effective in chronic HBV infection in various Phase II studies, such as small interfering RNA affecting envelopment (Figure 1), antisense oligonucleotide RNA, and anti-HBs antibodies, may prove to be beneficial in treating chronic HDV in future trials 191–196 . RNA interference pathway may inhibit viral genes and possibly cccDNA in chronic HBV infection 191 …”

Therapies against chronic hepatitis B infections: The times they are a-changin’, but the changing is slow!

“…Hepatol. 73, S20, , 2021bLim et al, 2022;Yuen et al, 2020bYuen et al, , 2021bYuen et al, , 2022bYuen et al, , 2022c. They mostly target the HBx region within genome, leading to virtual degradation of all HBV RNAs (due to 3'overlapping of all HBV RNAs), including RNAs coming from integrated HBV genomes; but recently RNAi targeting envelope protein genes have been R&Ded.…”